About Pyramid Bio
Pyramid Bio is a Healthcare company based in Waltham (United States) founded in 2015. It operates as a small molecules are developed for dermatology and oncology treatments. Pyramid Bio has raised $71.19 million across 5 funding rounds from investors including AUM 13F, Adage Capital Management and Prospect Hill Growth Partners. The company has 3 employees. Its focus areas include Life Sciences, Dermatology, Drugs and Aesthetics. Its legal entity is Pyramid Biosciences, Inc.,. Its competitors include Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte and 4 more; 8 of its 9 listed competitors have raised funding.
Company details
Pyramid Bio was founded in 2015 and is based in Waltham, United States. Small molecules are developed by the company for dermatology and oncology disorders. The lead candidate, PBI-100, functions as a selective TRK modulator with anti-inflammatory and antiproliferative effects and is advanced for psoriasis and atopic dermatitis in phase 1 trials. Another candidate, PBI-200, serves as a TRK inhibitor for solid and liquid tumors.
- Headquarters Waltham, United States
- Employees 3
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website pyramidbio.com
- Social LinkedIn
- Legal Name Pyramid Biosciences, Inc.,
- Total Equity Funding$71.19M (USD)
in 5 rounds
- Latest Funding Round$33.54M (USD), Series C
Oct 2021
- InvestorsAUM 13F
& 2 more
- Employee Count3
Funding Insights of Pyramid Bio
Pyramid Bio has successfully raised a total of $71.19M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $33.54 million completed in October 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $71.19M
- Total Rounds 5
- Last Round Series C — $33.54M
- First Round $3.63M
(Nov 2016)
- Investors Count 3
All 5 funding rounds of Pyramid Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2021 | $33.54M | Series C | – | – | – |
| Aug 2020 | $28M | Series B | – | Adage Capital Management, AUM 13F | – |
| Jul 2020 | $6M | Series B | – | – | – |
| Jul 2018 | $17,336 | Series A | – | – | – |
| Nov 2016 | $3.63M | Series A | – | – | – |
3 investors in total: 3 institutional.
Investors in Pyramid Bio
Pyramid Bio has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include AUM 13F, Adage Capital Management and Prospect Hill Growth Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Limited information is provided about the company's activities. | – | prospecthillgrowth.com | - | |
Offers investment management and secure information access to clients and partners. | 2001 | adagecapital.com | Boston, United States | |
Due diligence tools for asset managers | 2019 | aum13f.com | United States |
Investor details for Pyramid Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Pyramid Bio
19 people are tracked at Pyramid Bio (3 in leadership, 16 in board & advisors); the tracked headcount is 3.
| Name | Role | Group |
|---|---|---|
Jeffrey Wasserman | Chief Legal Officer | Leadership |
Biren Amin | Chief Financial & Strategy Officer | Leadership |
Nushmia Khokhar | Chief Medical Officer | Leadership |
Moses Chao | Scientific Advisor | Board & advisors |
Vlad Coric | Director | Board & advisors |
John Childs | Director | Board & advisors |
Timothy Cloughsey | Scientific Advisor | Board & advisors |
Daniel Cahill | Scientific Advisor | Board & advisors |
John Sampson | Scientific Advisor | Board & advisors |
Larry Feinberg | Director | Board & advisors |
David Reardon | Scientific Advisor | Board & advisors |
Lori Kunkel | Scientific Advisor | Board & advisors |
Michael Lim | Scientific Advisor | Board & advisors |
Dave Solit | Scientific Advisor | Board & advisors |
Katherine Warren | Scientific Advisor | Board & advisors |
Dana Farber | Scientific Advisor | Board & advisors |
Manmeet Ahluwalia | Scientific Advisor | Board & advisors |
George Demetri | Scientific Advisor | Board & advisors |
Aleksander Rabodzey | Director | Board & advisors |
Complete people profiles for Pyramid Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Pyramid Bio
3 dated milestones of Pyramid Bio across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Pyramid Bio is founded.
- Funding First funding round of $3.6M.
- Funding Latest funding round, Series C, of $33.5M.
Competitors of Pyramid Bio
Pyramid Bio has 9 listed competitors in our database, 8 of them funded. They include Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| adacap.com | 2002 | Saint Genis Pouilly, France | $56.13M | – | Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| revance.com | 2002 | Newark, United States | $154.56M | 597 | Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. |
Detailed competitors of Pyramid Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Dermatology
10 companies that operate in the same segment as Pyramid Bio (Dermatology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | 2002 | Newark, New Jersey, United States | USD 154.56 M | USD 234.04 M | 597 | |
Diagnostic tests for cancer prognosis are provided. | 2008 | Friendswood, Texas, United States | USD 61.97 M | USD 344.23 M | 761 | |
Developer of drugs for treating dermatology diseases | 1908 | Copenhagen, Denmark | USD 560.38 M | – | – | |
Skincare, beauty, and wellness services provided by VLCC across multiple countries. | 1989 | Delhi, Delhi, India | – | – | – | |
Adhesive patch biopsies for skin cancer detection are provided. | 1996 | San Diego, California, United States | USD 24.37 M | USD 15.3 M | 259 | |
AI-powered drug discovery platform for various diseases | 2016 | New York, New York, United States | USD 608.25 M | – | 197 | |
Immunotherapeutic solutions for dermatological conditions are developed. | 2016 | Westlake Village, California, United States | USD 94.5 M | USD 376.07 M | 342 | |
Targeted small molecules are developed for oncology treatments. | 2010 | Singapore, Singapore | USD 100 M | – | – | |
Pharmaceutical formulations for dermatology, gastroenterology, and wellness are manufactured. | 2014 | Pune, Maharashtra, India | USD 25.97 M | USD 18.15 M | 508 | |
Novel dermatologic therapies are developed for skin conditions. | 2012 | Malvern, Pennsylvania, United States | USD 82 M | USD 7.83 M | 64 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Pyramid Bio
Complete news archive for Pyramid Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pyramid Bio
Pyramid Bio was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Pyramid Bio is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Pyramid Bio is a funded company, having raised a total of $71.19M across 5 funding rounds to date. The company's 1st funding round was a Series A of $3.63M, raised on Nov 2016.
Pyramid Bio has 3 employees.
Pyramid Bio was founded in 2015 and is based in Waltham, United States. Small molecules are developed by the company for dermatology and oncology disorders. The lead candidate, PBI-100, functions as a selective TRK modulator with anti-inflammatory and antiproliferative effects and is advanced for psoriasis and atopic dermatitis in phase 1 trials. Another candidate, PBI-200, serves as a TRK inhibitor for solid and liquid tumors.
Pyramid Bio's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Pyramid Bio has 3 investors. Key investors include AUM 13F, Adage Capital Management, and Prospect Hill Growth Partners.
Pyramid Bio operates through Pyramid Biosciences, Inc.,.